poisar

Stocks · News reference

8-K filing — EyePoint, Inc. (EYPT)

SEC EDGAR

Filed: 2026-09-10 AccNo: 0001193125-26-387197 Size: 24 MB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

EYPT
Source
edgar
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Kessler Topaz Meltzer & Check, Llp

    EyePoint, Inc. (NASDAQ: EYPT) Alert: Investors Encouraged to Contact KTMC Law Firm

    EyePoint Inc. (NASDAQ: EYPT) announced disappointing Phase 3 clinical trial results for DURAVYU on August 17, 2026, failing to meet its primary endpoint in the LUGANO trial for wet age-related macular degeneration treatment. The stock subsequently dropped over 66%, prompting a securities litigation investigation by KTMC on behalf of affected investors.

    EYPT